

ABSTRACT

A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer.

5 According to the invention, the other anti-cancer agent is preferably chosen from:

- analogues of DNA bases such as 5-fluorouracil;
- Type I and/or II topoisomerase inhibitors such as for example camptothecin and its analogues, doxorubicin or amsacrine;
- compounds interacting with the cell spindle such as for example paclitaxel (Taxol);
- 10 - compounds acting on the cytoskeleton such as vinblastine;
- inhibitors of the transduction of the signal passing through the heterotrimeric G proteins;
- prenyltransferase inhibitors, and in particular farnesyltransferase inhibitors;
- cyclin-dependent kinase (CDKs) inhibitors;
- 15 - alkylating agents such as cisplatin;
- antagonists of folic acid such as methotrexate; and
- inhibitors of the synthesis of DNA and cell division cell such as mitomycin C.

A further subject of the invention is (1R)-1-[(2R)-2-amino-3-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-3-oxopropyl]dithiomethyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine, or a pharmaceutically acceptable salt thereof, useful as an anticancer agent.